Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Operating Expenses (2016 - 2026)

Protara Therapeutics' Operating Expenses history spans 14 years, with the latest figure at $19.6 million for Q1 2026.

  • Quarterly Operating Expenses rose 38.98% to $19.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $70.1 million through Mar 2026, up 36.22% year-over-year, with the annual reading at $64.5 million for FY2025, 31.32% up from the prior year.
  • Operating Expenses came in at $19.6 million for Q1 2026, up from $19.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $39.5 million in Q4 2022 to a low of $8.0 million in Q3 2022.
  • The 5-year median for Operating Expenses is $12.1 million (2023), against an average of $14.4 million.
  • Year-over-year, Operating Expenses skyrocketed 284.07% in 2022 and then plummeted 72.05% in 2023.
  • Protara Therapeutics' Operating Expenses stood at $39.5 million in 2022, then tumbled by 72.05% to $11.0 million in 2023, then rose by 29.63% to $14.3 million in 2024, then soared by 33.31% to $19.1 million in 2025, then increased by 2.88% to $19.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Operating Expenses are $19.6 million (Q1 2026), $19.1 million (Q4 2025), and $14.8 million (Q3 2025).